Glenmark Pharma Reports Significant Growth in Net Sales and Profit for March 2026
Glenmark Consolidated March 2026 Net Sales at Rs 3,770.59 crore, up 15.8% Y-o-Y
Image: Moneycontrol
Glenmark Pharmaceuticals achieved consolidated net sales of ₹3,770.59 crore for March 2026, marking a 15.8% increase from the previous year. The company's net profit surged to ₹301.41 crore, reflecting a remarkable 6382.02% rise compared to March 2025.
- 01Glenmark's EBITDA reached ₹951.68 crore, a 66.17% increase from the previous year.
- 02Earnings per share (EPS) rose to ₹10.68, up from ₹0.16 in March 2025.
- 03The company's shares closed at ₹2,184.60 on June 1, 2026, with a 10.41% return over the last six months.
- 04Total income from operations was ₹3,770.59 crore, up from ₹3,256.21 crore in March 2025.
- 05Glenmark's expenditure on raw materials decreased to ₹731.20 crore, down from ₹794.78 crore in the previous year.
Advertisement
In-Article Ad
Glenmark Pharmaceuticals reported impressive financial results for the quarter ending March 2026, with consolidated net sales reaching ₹3,770.59 crore, a 15.8% increase from ₹3,256.21 crore in the same period last year. The net profit skyrocketed to ₹301.41 crore, marking a staggering 6382.02% rise from just ₹4.65 crore in March 2025. The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) also saw a significant boost, totaling ₹951.68 crore, which is a 66.17% increase compared to the previous year. Additionally, Glenmark's earnings per share (EPS) improved dramatically to ₹10.68 from ₹0.16. As of June 1, 2026, Glenmark shares were priced at ₹2,184.60, yielding a 10.41% return over the last six months and 45.88% over the past year. Overall, these results reflect a robust growth trajectory for Glenmark Pharma.
Advertisement
In-Article Ad
Glenmark's strong financial performance may lead to increased investor confidence and potentially higher stock prices, benefiting shareholders.
Advertisement
In-Article Ad
Reader Poll
What do you think about Glenmark's financial performance?
Connecting to poll...
More about Glenmark Pharmaceuticals
Read the original article
Visit the source for the complete story.